Curis Begins Phase 1 Trial of Anti-Tumor Drug
Ryan McBride8/26/08
Drug developer Curis (NASDAQ:CRIS), of Cambridge, MA, reported today that it has begun a Phase 1 clinical trial of an anti-cancer small molecule, dubbed CUDC-101. The experimental drug is designed to inhibit tumor cell growth and survival, and 18 to 40 patients are expected to enroll in the clinical trial.
Valley’s TGen has new way to attack tumors Uterine drug halts deadly cells’ growth | OncoBlog.com
9/1/08 1:01 pm
[...] Curis Begins Phase 1 Trial of Anti-Tumor Drug [...]